---
title: "Bio-Techne Corp reports results for the quarter ended June 30 - Earnings Summary"
description: "Bio-Techne Corp reported adjusted earnings of 53 cents per share for the quarter ended June 30, exceeding last year's 49 cents and analysts' expectations of 50 cents. Revenue increased by 3.5% to $316"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251864610.md"
published_at: "2025-08-06T14:31:05.000Z"
---

# Bio-Techne Corp reports results for the quarter ended June 30 - Earnings Summary

> Bio-Techne Corp reported adjusted earnings of 53 cents per share for the quarter ended June 30, exceeding last year's 49 cents and analysts' expectations of 50 cents. Revenue increased by 3.5% to $316.96 million, slightly above the expected $315.60 million. However, the company reported a loss of 11 cents per share and a quarterly loss of $17.68 million. Despite a 6.2% rise in shares this quarter, they have fallen 24.1% year-to-date. Analysts maintain a "buy" rating with a median 12-month price target of $65.00, 15.9% above the last closing price of $54.64.

-   Bio-Techne Corp (TECH.OQ) reported quarterly adjusted earnings of 53 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 49 cents. The mean expectation of sixteen analysts for the quarter was for earnings of 50 cents per share. Wall Street expected results to range from 47 cents to 52 cents per share.
-   Revenue rose 3.5% to $316.96 million from a year ago; analysts expected $315.60 million.
-   Bio-Techne Corp’s reported EPS for the quarter was a loss of 11 cents​.
-   The company reported a quarterly loss of $17.68 million.
-   Bio-Techne Corp shares had risen by 6.2% this quarter and lost 24.1% so far this year. FORECAST CHANGES
-   The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​
-   In the last 30 days, three analysts negatively revised earnings estimates RECOMMENDATIONS
-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 13 “strong buy” or “buy,” 6 “hold” and no “sell” or “strong sell.” The average consensus recommendation for the biotechnology & medical research peer group is also “buy”
-   Wall Street’s median 12-month price target for Bio-Techne Corp is $65.00, about 15.9% above its last closing price of $54.64 This summary was machine generated from LSEG data August 6 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

### MISSED

Jun. 30 2025 0.50 0.53 Beat

Mar. 31 2025 0.51 0.56 Beat

Dec. 31 2024 0.39 0.42 Beat

Sep. 30 2024 0.38 0.42 Beat

### Related Stocks

- [TECH.US - Bio-Techne](https://longbridge.com/en/quote/TECH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 華爾街分析師對 Bio-Techne 股票設定的目標價是多少？ | 華爾街分析師對 Bio-Techne 股票的目標價格是多少？ | [Link](https://longbridge.com/en/news/275639173.md) |
| Bio-Techne 任命 Steve Crouse 為診斷和空間生物學部門總裁 | Bio-Techne 公司宣佈，馬特·麥克馬努斯博士將於 2026 年 3 月 1 日辭去診斷與空間生物學部門總裁職務。目前擔任分析解決方案部門高級副總裁的史蒂夫·克勞斯已被任命接替他擔任此職務 | [Link](https://longbridge.com/en/news/275618046.md) |
| Bio-Techne｜8-K：2026 財年 Q2 營收 2.96 億美元超過預期 |  | [Link](https://longbridge.com/en/news/274802927.md) |
| Bio-Techne：短期的韌性和利潤率的擴張支持其加速增長，並維持買入評級直至 2027 年 | 花旗分析師 Patrick B Donnelly 對 Bio-Techne 維持買入評級，目標價為 80.00 美元。他提到短期內的韌性和中期前景的改善，預計到 2026 財年第四季度有機增長將加速至中個位數。支持這一觀點的因素包括更容易的 | [Link](https://longbridge.com/en/news/274873127.md) |
| 生物技術公司 Bio-Techne 由於關鍵部門的強勁表現，超出了季度預期 | 生物技術公司 Bio-Techne 的第二季度收入和利潤超出了分析師的預期，主要得益於其藥物開發產品的強勁需求。該公司報告收入為 2.96 億美元，超過了 2.9019 億美元的預測，其蛋白質科學部門的增長顯著，達到了 2%。儘管其診斷和基 | [Link](https://longbridge.com/en/news/274818514.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.